Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Efficacy of Conjugated Estrogens & Bazedoxifene

Menopause; ePub 2016 May 9; Pinkerton, et al

Conjugated estrogens (CE) and bazedoxifene (BZA) had a similar and beneficial impact on hot flushes, menopause-specific quality of life (MENQOL), and bone mineral density (BMD) in minorities and whites in a study of 2,907 white, 315 black, and 202 Hispanic women randomized to CE 0.45 or 0.625 mg/BZA 20 mg or placebo in pooled analysis. The goal of the study was to compare efficacy of CE/BZA for treatment of menopausal symptoms and prevention of postmenopausal osteoporosis in minorities vs whites. Researchers found:

• Reduction in a hot flush frequency/severity vs placebo was similar in white and minority women.

• In both populations, both doses significantly improved MENQOL vasomotor function, sexual function, and total scores at 3 months, decreased the percentage of parabasal cells at 2 years, and increased the percentage of BMD responders at 12 and 24 months.

• Significant differential treatment effects by race/ethnicity were observed for effects on vaginal superficial cells at month 24 and vaginal pH at month 3.

Citation: Pinkerton JV, Pickar JH, Ryan KA, Yu CR, Mirkin S, Komm BS. Conjugated estrogens and bazedoxifene in minority populations: Pooled analysis of four phase 3 trials. [Published online ahead of print May 9, 2016]. Menopause. doi:10.1097/GME.0000000000000617.